Jonathan Ilowite, MD
Pulmonary Disease · New Hyde Park, NYNPI 1356403364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,849 of the $1,849 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Boehringer Ingelheim.
Across 1 payment — averaging $1849.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
Across 228 payments — averaging $3074.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$211K
- GSK$188K
- Astrazeneca AB$157K
- Insmed, Inc.$85K
- Sanofi US Services Inc.$54K
- Genentech, Inc.$5K
- plus $2K from 2 others
What the payments were for
- Speaking & faculty fees$1,849100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 1 | $1,849 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$1,849
How this compares
$1,849 in reported general payments places this provider in the 60th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 235 | $169,410 |
| NucalaMepolizumab | 13 | $139,846 |
| TezspireTezepelumab-Ekko | 27 | $117,379 |
| Dupixent SyringeDupilumab | 18 | $72,519 |
| Breo ElliptaFluticasone/Vilanterol | 90 | $38,253 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 78 | $36,404 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,787 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $6,922 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,613 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,420 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 152 | $5,110 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 24 | $4,294 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,568 |
| Fluticasone Propionate | 112 | $1,170 |
| Mycophenolate Mofetil | 17 | $641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat | $1,849 | $6,42012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New Hyde Park
- Abhinav AgrawalNew Hyde Park$55K
- Jeffrey WolfGreat Neck$892K
- Keith HarrisPort Jefferson Station$832K
- Jack MannBayside$736K
- Raji AyinlaBronx$673K
- Charles PowellNew York$654K
- Nashat RabadiBuffalo$613K
- Craig ThurmJamaica$604K
- Michael MandelLarchmont$589K
- Sherif El BayadiSyracuse$571K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.